Lido Advisors
TELO icon

Lido Advisors’s Telomir Pharmaceuticals TELO Stock Holding History

Lido Advisors’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,000
Closed -$77.3K – 1491
2024
Q1 		$77.3K Buy
+15,000
New +$113K ﹤0.01% 1334

Other funds holding TELO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BHWM
Beaird Harris Wealth Management Dallas, Texas $1.6B AUM 16.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Lido Advisors's TELO Position: Q2 2024 in Review

Lido Advisors sold out of Telomir Pharmaceuticals (TELO) in Q2 2024, closing a stake of 15,000 shares — an estimated $77.3K sold.

Lido Advisors first reported a position in TELO in Q1 2024 and held it in 1 quarter. The position peaked at $77.3K in Q1 2024. 25 funds tracked by Wall St. Rank hold TELO as of Q2 2024.

  • Lido Advisors reported no remaining Telomir Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Lido Advisors sold 15,000 Telomir Pharmaceuticals shares in Q2 2024, an estimated $77.3K.
  • Lido Advisors first reported a position in Telomir Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Lido Advisors's Telomir Pharmaceuticals position peaked at $77.3K in Q1 2024.
  • 25 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2024.

Based on Lido Advisors's 13F filing for Q2 2024, filed 15 Aug 2024.